Background. A brief period of myocardial ischemia can result in an increased resistance to subsequent,
B rief periods of ischemia can render the heart more resistant to subsequent, more severe episodes of ischemia.'-3 The protective effects of myocardial preconditioning have been demonstrated in several mammalian species including dogs, rabbits, and pigs.1-3 Investigations are currently ongoing to determine the mechanism of preconditioning. Several investigators have shown that preconditioning does not induce an increased collateral blood flow into the ischemic region.14 Several studies have indicated that adenosine may be mediating preconditioning, apparently via Al-receptor activation.35 Selective Al-receptor antagonists have been shown to abolish preconditioning, and Al-agonists appear to mimic preconditioning. 3, 5 The mechanism in which A,-activation can protect ischemic tissue is unknown, although some evidence indicates an involvement of a Gi protein pathway. 6 Recent evidence has indicated a link between adenosine receptors and myocardial ATP-sensitive potassium channels (KATP). In myocytes, Al-receptor activation can open KATP via a Gi protein-mediated process.7 In agree-ment with these data are several reports indicating that coronary reactive hyperemia and adenosine-induced increases in coronary blood flow can be attenuated by the KATP blocker glyburide (glibenclamide).8 Since several laboratories have shown that pharmacological activation of KATP can protect ischemic myocardial tissue in several species,9-11 this may explain how activation of Al-receptors can protect ischemic myocardium. With this in mind, Gross and associates4'2 found that the structurally dissimilar KATP blockers glyburide and sodium 5-hydroxydecanoate abolished preconditioning in dogs. Unfortunately, work from another group has shown glyburide to be ineffective in abolishing preconditioning in rabbits. 13 Thus, the role of KAT activation in mediating preconditioning is still debatable. The purpose of the present study was to determine whether glyburide can abolish preconditioning in a canine model of ischemia and reperfusion. In addition, we also determined whether the cardioprotective effects of A,-stimulation can be blocked by glyburide. The results of this study will further define the role of KATP activation in preconditioning.
Methods

Surgical Preparation
Mongrel dogs of either sex (weight, [10] [11] [12] [13] [14] [15] [16] [17] kg) were anesthetized with intravenous sodium pentobarbital (30 mg/kg), and a catheter was placed into the right femoral artery for collection of blood samples. A Millar Mikrotip catheter pressure transducer (Millar Instruments Inc., Houston, Tex.) was placed into the left femoral artery and advanced into the aortic arch for the measurement of arterial blood pressure. An endotracheal tube was placed into the trachea, and the animals were artificially respired such that eucapnia was maintained. Eucapnia (Pco2 35-40 mm Hg) and normoxia (>70 mm Hg) were maintained throughout the experiment by continuous monitoring of arterial blood gases using an ABL 4 blood gas analyzer (Radiometer, Copenhagen).
A left thoracotomy was performed at the fifth intercostal space, and the heart was exposed. The left circumflex coronary artery (LCx) was isolated proximal to its first branch, and a silk suture was placed around it for later occlusion. A catheter was placed into the left atrial appendage for dye and radioactive microsphere injection. A catheter was also placed into the LCx distal to the coronary snare, and this was to be used for intracoronary infusion of drug or vehicle. The catheter consisted of a bent 27-gauge needle with polyethyene tubing attached.
The animals were allowed to stabilize for 5-10 minutes, at which time an arterial blood sample was removed anaerobically for measurement of blood gases. Arterial blood pressure, heart rate, and ECG were measured. At this time, myocardial blood flow was measured using radioactive microspheres ("3Sn, 57Co, 85Sr, or 4Sc; 15+3 ,um; New England Nuclear Company, Wilmington, Del.). Animals that were to be preconditioned were subjected to a 5-minute LCx occlusion followed by 10 minutes of reperfusion. The LCx was then completely occluded for a total of 60 minutes in all groups. Myocardial blood flow was determined 40 minutes after the initiation of the second LCx occlusion. At 60 minutes after occlusion, the LCx was reperfused. After 1 hour of reperfusion, myocardial blood flow was again measured.
The reperfusion was continued for a total of 5 hours, at which time the LCx was cannulated and perfused at the animal's existing pressure with Ringer's lactate for determination of the area at risk. Patent blue violet dye (1 mg/kg of a 10 mg/ml solution) was injected into the left atrial catheter, and the heart was quickly excised. The atria were trimmed away, leaving only the ventricles. The ventricles were then cut transversely into 0.5-cm slices. In another group of animals, the interaction between Al-receptors and KATP in the above infarction model was determined. The animals were divided into three groups: group 1, animals given vehicle (50% polyethylene glycol in water, n=7); group 2, animals given 0.4 ,ug/kg/min R-PIA (R(-)-N6-(2-phenylisopropyl) adenosine, Research Biochemicals Inc., Natick, Mass.) (n =7); and group 3, animals given 5 ,g/kg/min glyburide+0.4 ,ug/kg/min R-PIA (n=6). The various treatments were administered directly into the LCx. None of the animals in this group were subjected to preconditioning, although a similar time course was allowed as for preconditioned animals. The infusion of R-PIA was given as an infusion over 15 minutes before LCx occlusion, and glyburide was infused over 20 minutes before LCx occlusion. Thus, glyburide infusion was begun 5 minutes before R-PIA infusion. After drug treatment, the animals were subjected to 60 minutes of LCx occlusion and 5 hours of reperfusion, as described above. The dose of R-PIA was selected as the highest dose in which no heart rate effects were observed. As above, the total volume of vehicle and drug groups was the same with the animals receiving a total volume of 10 ml.
Statistics
Changes in hemodynamic, blood flow, and infarct size variables were analyzed using ANOVA. Multiple comparisons were done using the Newman-Keuls test. Linear regression analysis was used to evaluate the relation between LV area at risk versus LV infarct size and LV infarct size as a percent of area at risk versus subendocardial collateral blood flow. ANCOVA was used to determine differences in these relations for the various drug treatments. This form of infarct size analysis has flows were calculated from these counts.
been previously described in detail.14,15For all analyses, 
Results
Effect of Glyburide on Preconditioning
The effect of glyburide and preconditioning on myocardial infarct size and LV area at risk are shown in Figure 1 . Table 1 . No significant differences for baseline myocardial blood flows were noted between groups for any region measured. LCx occlusion caused a significant reduction in blood flow into the LCx perfused region, and the flow decrement was most severe in the subendocardial region. No differences in collateral blood flow were observed between any of the groups. During LCx occlusion, blood flow into the nonischemic region was slightly increased in all groups, but in general, this increase in flow was not significant. During reperfusion, flow into the previously ischemic region returned toward preischemic control levels in all groups. In Figure  2 , the relation between infarct size as a percent of the area at risk and collateral flow into the inner half of the myocardium (subendocardium) for all groups is shown. A significant negative correlation was observed for the vehicle control group, and preconditioning significantly altered the regression line, indicating that at a given collateral flow, myocardial infarct size was reduced. The curves for both glyburide-treated groups were not significantly different from vehicle. The group given glyburide without preconditioning showed a slight increase Table  2 . None of the drug or vehicle treatments resulted in significant changes in heart rate. Ischemia and reperfusion also did not alter heart rate in any of the groups studied. Both systolic and diastolic arterial blood pressures were unchanged throughout the experiment in all groups. No significant differences in blood pressure were observed between any of the groups.
Effect of Glyburide on the Cardioprotective Action of R-PIA Hemodynamic data for all groups in this series are shown in Table 3 . Baseline heart rates and arterial blood pressures were similar for all groups before drug treatment or ischemia. No changes in heart rate were observed in any group after drug treatment. Ischemia did not significantly alter heart rate in any group. In all groups, heart rate tended to increase with time after reperfusion, although the increases did not achieve statistical significance. Treatment with R-PIA with or without glyburide did not affect arterial blood pressure before or during ischemia. Systolic and diastolic blood pressures were significantly reduced late into reperfusion, and similar reductions were observed for all treatment groups.
Myocardial infarct size and area at risk data for all groups are shown in Figure 3 . LV area at risk was found to be similar in all groups, indicating similar anatomical regions. R-PIA was found to significantly reduce infarct size as a percent of the area at risk. Glyburide completely abolished this protective effect. The dose of glyburide used was found to have no effect, when given alone, on infarct size in the preceding series of experiments. A significant correlation between infarct size and area at risk was observed in vehicle control animals (data not shown). This was also true for R-PIA plus glyburide. The relation for R-PIA alone was not as clear, as a much smaller degree of variability in infarct size was accounted for by area at risk. The R-PIA curve was significantly shifted to the right relative to vehicle controls, and both the y-intercept and slope were significantly different. The relation between LV infarct size as a percent of the area at risk and subendocardial collateral flow is shown in Figure 4 . A significant relation was observed for vehicle controls, and a similar dial blood flow were observed between any groups. Blood flow into the LCx perfused region was significantly reduced during ischemia, particularly in the subendocardial region, and no differences in this collateral flow were observed for any group. At 1 hour into reperfusion, blood flow into the LCx region of vehicle-treated hearts was only partially restored, the reflow into the subendocardium being the lowest. In R-PIA-treated hearts, reflow into the LCx region returned nearly to preischemic values, and this increase was significantly higher in the subendocardium and subepicardium relative to vehicle. Cotreatment with glyburide resulted in a loss of the improved reflow observed for R-PIA alone. Discussion Brief periods of myocardial ischemia have been shown to result in an increased resistance of the affected region to subsequent, more severe episodes of ischemia.1-3 This effect, termed preconditioning, has been shown in dog, rabbit, pig, and rat hearts.'-3,16 Preconditioning can be observed in hearts subjected to only several minutes of ischemia; however, the protective effects appear to last several hours.'7 The protective mechanism of action does not appear to result from an increased collateral flow or from reduced oxygen demand secondary to contractile stunning.' Recent studies have indicated that activation of adenosine Al-receptors may be responsible for the preconditioning effect.3,5 This is based on the reversal of preconditioning by selective Al-receptor blockers5 and the protective effects of A,-agonists.' Presently, the exact mechanism in which A,-activation can result in protection is not well understood, although preconditioning is associated with a reduced ATP utilization or a metabolite accumulation. '7 Recent studies by Kirsch et To establish a link between preconditioning and KATP activation, Gross's group4'12 has shown that the KATP blockers glyburide and sodium 5-hydroxydecanoate completely abolish preconditioning in a canine model of ischemia and reperfusion. The doses of the blockers used in these studies were found to have no effect on infarct size when given to animals not subjected to preconditioning. Conversely, Thornton et al13 found that glyburide did not abolish preconditioning in rabbits despite a proischemic effect observed when it was given to nonpreconditioned animals. They also could not show a protective effect for the KATP opener pinacidil, unlike studies from our laboratory and others.9-1" At the present time, it is difficult to reconcile the results in rabbits with the results observed in dogs. It was of interest that in the rabbit study, glyburide alone was found to result in a significant proischemic effect but still did not abolish preconditioning. If glyburide was proischemic, the interesting question was why the KATP opener pinacidil did not protect the ischemic myocardium, unless the dose used was too low. Although it is possible to speculate that glyburide may have other activities that may make it proischemic, studies have indicated that glyburide is selective in blocking KATP in ischemic myocardium.2' It is also possible that species differences may exist.
We thus considered the question of the role of KATP in preconditioning worth reexamining. We chose the dog because of its known response to preconditioning and also because more is known about its myocardial KATP compared with species such as the rabbit. We determined the ability of glyburide to abolish preconditioning in the present study. We found that a 5-minute period of LCx occlusion resulted in a significant protective effect when the same region was exposed to a subsequent 60-minute period of occlusion. As shown previously by several investigators, this protective effect was not accompanied by an increase in collateral flow into either the subendocardium or subepicardium."4 Glyburide was given in a dose that when given to nonpreconditioned dogs had little effect on the outcome of the ischemic event relative to vehicle- We are confident that in the dog, KATP activation can mediate at least some of the protective effect of preconditioning. We also attempted to link the work indicating A,-stimulation and work indicating KATP activation in mediating preconditioning. Studies from several laboratories have shown that A,-antagonists can abolish preconditioning in several species, including the dog.5. 22 Gross and Auchampach22 showed that an Al-receptor antagonist abolishes preconditioning in a canine model of preconditioning that is virtually identical with our model. We extended this observation by determining the effect of glyburide on the cardioprotective effects of the Al-agonist R-PIA. We did not determine the effect of A1-antagonists on preconditioning, as this has been done by several investigators (unlike the effect of glyburide, which was more controversial). Like several previous studies,3,23,24 we have shown R-PIA to reduce infarct size, and this appears to be protective despite a lack of effects on collateral flow. Several studies have indicated that adenosine also has protective effects in several models of ischemia,14,23 as 
